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Introduction
Intracerebral hemorrhage (ICH) accounts for 15% or more
of all strokes, but the proportion could have been
underestimated in most stroke incidence studies. Primary ICH,
in which there is no identifiable underlying cause for the
hemorrhage, has a higher early case fatality than ischemic
stroke. After primary ICH, only 38% of affected people
survive the first year.7) Although guidelines for supportive care
exist,1) there is currently no treatment that has been shown in a
randomized controlled trial to improve outcome after ICH. 
The volume of the hematoma is an important determinant
of mortality and functional outcome after ICH and early
hematoma growth is an important cause of neurological
deterioration.2)3)12) Approximately one third of ICHs enlarge
by a third within three to 24 hours after onset.3) Early ICH
growth occurs in the absence of coagulopathy and appears to
result from continued bleeding or rebleeding at multiple sites
within the first few hours after onset.17) The only prospective
study of this phenomenon revealed a > 33% increase in ICH
volume in 26% of patients at 1 hour, and in an additional
12% between 1 and 20 hours.3)
Hematoma volume is a critical determinant of mortality
and functional outcome after ICH,6) and intervention with
ultra-early hemostatic therapy in the emergency setting
could potentially improve outcome after ICH by arresting
ongoing bleeding and minimizing hematoma growth. Apart
from attempting to improve ICH outcome by limiting ICH
volume with surgical intervention, treating both the
perihematomal edema and ischemic penumbra surrounding
an acute ICH are other potential therapeutic targets. Steroids
have not proven beneficial for the acute treatment of ICH;
the trials revealed that the 95% confidence intervals around
the overall estimate of treatment effect encompassed
clinically significant harm or benefit.9) Nor have osmotic
diuretics proven beneficial for the treatment of edema due to
ICH in a randomized controlled design.18) Thrombin is
thought to be the most potent promoter of perihematomal
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edema, and thrombin inhibitor may counteract this, although
they are as yet untested in a randomized controlled design.11) 
Recombinant factor VIIa (rFVIIa) act at sites of tissue and
endothelial injury by binding to both exposed tissue factor and
activated platelets, thereby generating thrombin, with a half
life of two to three hours. rFVIIa is currently approved to treat
bleeding in hemophilia patients with inhibitors to factors VIII
or IX, and is approved in Europe for the treatment of factor
VII deficiency and Glanzmann thrombasthnia. Furthermore, a
large number of case series studies and anecdotal evidences,
from patients with different bleeding conditions, have now
shown that rFVIIa is actually a valuable general hemostatic
agent. Although thromboembolic complications related to
rFVIIa administration have occurred, with >400,000 doses
administered for a growing number of clinical uses, the
frequency of serious adverse events remains <1%.20)
Herein, we reviewed of the published articles specifically
addressing clinical trials of rFVIIa treatment for acute ICH
and evaluate the safety and feasibility of it. 
Materials and Methods
The literature used for this review was identified using the
Medline database (PubMed, http://www.ncbi.nlm.nih.gov/
PubMed/). A systematic review of all language literature
was carried out. The following English keywords were used
for the search: intracerebral hemorrhage and VII. This query
yielded 137 results. In advanced search with human study
and English in language, 104 results were identified, and
title and abstract were carefully reviewed. Seven articles of
these was a clinical trial of rFVIIa for acute ICH.6)8)10)14-16)21)
Full text articles were procured where possible. 
After careful review of the seven articles, there was three
randomized, controlled clinical trials and one cohort study.
Three randomized, controlled clinical trials (Table 1) was
Recombinant Activated Factor VII Intracerebral
Hemorrhage Trial Investigators,6)14) Europe/AustralAsia
NovoSeven ICH Trial Investigators,15) and US phase IIA
trial.16) One cohort study was Genetic and Environmental
Risk Factors for Hemorrhagic Stroke (GERFHS) Study.10)
One article was focused on the intraventricular hemorrhage,
not ICH.21) Another one article was examined the cost-
effectiveness of early treatment with rFVIIa for ICH.8)
In this review, we analyzed three randomized, controlled
clinical trials and one cohort study. 
Results
Results of included studies are summarized on Table 2.
Overall, treatment with rFVIIa within four hours after the onset
of ICH limits the growth of the hematoma, reduces mortality,
and improves functional outcomes at 90 days, despite a small
increase in the frequency of thromboembolic adverse events. 
Europe/AustralAsia Trial Investigators15) reported that ICH
volume change between baseline and 24 hours was not
different and clinical outcome between baseline and 90 days
was not significant. However, the method of randomization
was not specified and there was imbalance in the baseline
ICH volume between placebo and treatment groups.
US phase IIA trials16) tested the safety of the rFVIIa
treatment. 33 patients experienced 186 adverse events,
which occurred with similar frequency in each patients and
placebo groups. Ten thromboembolic adverse events were
composed of one deep thrombosis, one cerebral infarction,
one pulmonary embolism, and six ischemic electrocardiogram
changes or cardiac enzyme elevation. There were no
coagulopathy or dose-related increase in edema-to-ICH
volume ratio. However, the method of randomization wa not
specified on this trial and the participants was too small. 
Genetic and Environmental Risk Factors for Hemorrhagic
Stroke (GERFHS) Study of Canadian Stroke Network10)
revealed that mortality at 90 days among potentially eligible
patients was the same as for the placebo group in the rFVIIa trial
(29% versus 29%; P=0.99). However, the absolute mortality
benefit for rFVIIa patients compared with placebo patients in the
trial was 11% (P=0.02). Death or severe disability at 3 months
occurred in 69% of placebo patients and 53% of rFVIIa-treated
patients (P=0.004). However, this cohort study had several
limitations. The inclusion and exclusion criteria of the study
were ambiguous and the data collection was retrospective.
Values were sometimes missing or not aggressively pursued by
attending physicians when deemed irrelevant to patient care. 
Recombinant Activated Factor VII Intracerebral Hemorrhage
Trial Investigators6)14) was a randomized (4/block, sequentially
numbered, identical-appearing containers), placebo-controlled,
phase IIB, dose-ranging, ‘proof-of-concept’study, regardless
of funding by Novo Nordisk. One recent report of this clinical
trial6) revealed that hematoma growth is an independent
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Table 1. Characteristics of included studies
Study Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators6)14)
Methods Parallel group, randomized (4/block, sequentially numbered, identical-appearing containers), double-blind,
placebo-controlled, phase IIB, dose-ranging, ‘proof-of-concept’study
Participants Inclusion criteria: age 18 years or older; spontaneous ICH within three hours of onset
Exclusion criteria: GCS 3 to 5; planned surgical evacuation of hematoma within 24 hours after admission;
secondary ICH with known underlying cause; known use of oral anticoagulant agents; known thrombocytopenia;
history of coagulopathy; acute sepsis; crush injury; DIC; pregnancy; preexisting disability (mRS >2 pre-ICH);
symptomatic thrombotic or vaso-occlusive disease within 30 days before onset of ICH
Interventions Recombinant activated factor VII (NovoSeven) at doses of (40 μg/kg, 80 μg/kg or 160 μg/kg) versus placebo,
within one hour of baseline CT and no latter than four hours after ICH onset
Outcomes Percentage change in ICH volume on CT from baseline to 24 hours; mRS 4 to 6 or GOS-E 1 to 4 at 90 days;
adverse events in hospital and serious adverse events until day 90
Study Europe/AustralAsia NovoSeven ICH Trial Investigators15)
Methods Parallel group, randomized, placebo-controlled, phase IIA dose escalation safety and feasibility study
Participants Inclusion criteria: age 18 years or older; spontaneous ICH within three hours of onset
Exclusion criteria: GCS 3 to 5; surgical hematoma evacuation planned or performed within 24 hours; secondary
ICH with known underlying cause; known oral anticoagulant use; coagulopathy; thrombocytopenia; history or
acute evidence of thrombotic, hypercoagulable, or vaso-occlusive disease; acute sepsis or crush injury;
pregnancy; known malignant disease or alcohol abuse; preexisting disability (mRS >2 pre-ICH); known or
suspected allergy to trial product; participation in another trial
Interventions Recombinant activated factor VII (NovoSeven) at doses of (10 μg/kg, 20 μg/kg, 40 μg/kg, 80 μg/kg or 160 μg/kg)
versus placebo, within one hour of baseline CT 
Outcomes Adverse events at days 1 to 5, 15 (or discharge), and 90; change in ICH +/- IVH volume on CT between baseline
and 24 hours; ICH growth (>33% or 12.5 ml); drop of > 1 GCS point or increase of > 3 NIHSS points days 0 to 5;
dead versus alive with little disability (Barthel index 95 to 100, GOS-E 8, mRS 0 to 2) versus alive and functionally
independent (Barthel Index 60 to 100, GOS-E 5 to 8, mRS 0 to 3) at day 90
Study US phase IIA trial16)
Methods Parallel group, randomized, double-blind, placebo-controlled, phase IIA dose escalation safety study
Participants Inclusion criteria: age 18 years or older; spontaneous ICH within three hours of onset
Exclusion criteria: GCS 3 to 5; planned surgical evacuation of hematoma within 24 hours; secondary ICH with
known underlying cause; known use of oral anticoagulant agents; known thrombocytopenia; history of
coagulopathy; acute sepsis; crush injury; DIC; pregnancy; preexisting disability (mRS >2 pre-ICH); symptomatic
thrombotic or vaso-occlusive disease within 30 days before onset of ICH, known or suspected allergy to trial
product; participation in another trial
I nterventions Recombinant activated factor VII (NovoSeven) at doses of (5 μg/kg, 20 μg/kg, 40 μg/kg, or 80 μg/kg) versus
placebo, within four hours of ICH onset 
Outcomes Serious adverse events; coagulation parameters; perihematomal edema; ICH volume ratio on CT; change in ICH
volume from baseline on CT; change in ‘neurological scores’
Study Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS) Study10)
Methods Large, population-based cohort study
Participants Inclusion criteria: age 18 years or older; spontaneous ICH within three hours of onset, drug administration within
one hour of CT scan
Exclusion criteria: History of thrombotic or vaso-occlusive disease; GCS 3 to 5; INR ≥1.4 or PTT > 35; Baseline mRS
>2; Surgical drainage within 24 hours; ICH from aneurysm or vascular malformation; Platelet count ≤50000;
coagulopathy, DIC or hypercoagulable state; pregnancy; crush injury; acute sepsis
Interventions Recombinant activated factor VII (NovoSeven) at doses of (5 μg/kg, 20 μg/kg, 40 μg/kg, or 80 μg/kg) versus
placebo, within one hour of ICH onset 
Outcomes Serious adverse events, Mortality at 90 days
GCS: Glasgow Coma Scale, ICH: intracerebral hemorrhage, DIC: Disseminated intravascular coagulation, mRS: modified Rankin scale,
GOS-E: Extended Glasgow Outcome Scale, IVH: intraventricular hemorrhage, NIHSS: National Institutes of Health Stroke Scale, INR:
international normalized ratio, PTT: partial thromboplastin time.
determinant of both mortality and functional outcome after
ICH. And they concluded that attenuation of growth is an
important therapeutic strategy. Another recent report14) revealed
that ultra-early hemostatic therapy with rFVIIa limited the
growth of hemorrhage, reduced mortality, and improved
functional outcomes after ICH. Hematoma volume increased
more in placebo group than in the rFVIIa groups. The mean
increase was 29% in the placebo group, as compared with
16%, 14%, and 11% in the groups given 40 μg, 80 μg, and 160
μg of rFVIIa per kilogram, respectively (P=0.01). Growth in
the volume of ICH was reduced by 3.3 ml, 4.5 ml, and 5.8ml in
the three treatment groups, as compared with that in the
placebo group (P=0.01). Mortality at 90% was 29% for patients
who received placebo, as compared with 18% in the three
rFVIIa groups combined (P=0.02). Serious thromboembolic
adverse events, mainly myocardial or cerebral infarction,
occurred in 7% of rFVIIa-treated patients, as compared with
2% of those given placebo (P=0.12). 
Discussion
rFVIIa is a vitamin-K-dependent glycoprotein with a
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Table 2. Results of included studies
Study (reference) Participants Results
Recombinant Activated Factor Patient: 103 䤎 Percentage of hematoma growth, initial ICH volume, GCS, and IVH were 
VII Intracerebral Hemorrhage Placebo: 115 all associated with increased mortality
Trial Investigators6) 䤎 Percentage growth, initial ICH volume, GCS, and age predicted outcome.
䤎 Gender, location, blood glucose, and blood pressure did not predict
outcome.
Recombinant Activated Factor Patient: 399 䤎 Hematoma volume: increased more in the placebo group than in 
VII Intracerebral Hemorrhage 40μg/kg: 108 rFVIIa group 
Trial Investigators14) 80μg/kg: 92 䤎 Mean increase: 29% in placebo group, 16%, 14%, and 11% in groups
160μg/kg: 103 given 40μg/kg, 80μg/kg or 160μg/kg of rFVIIa, respectively (P=0.01)
Placebo: 96 䤎 Growth in volume of ICH: reduced by 3.3ml, 4.5ml, and 5.8ml in groups
given 40μg/kg, 80μg/kg or 160μg/kg of rFVIIa, respectively (P=0.01)
䤎 Mortality or Severe disability (mRS 4 to 6): 69% in placebo group, 55%.
49%, and 54% in groups given 40μg/kg, 80μg/kg or 160μg/kg of rFVIIa,
respectively (P=0.004)
䤎 Mortality at 90 days: 29% in placebo group, 18% in rFVIIa group (P= 0.02)
䤎 Serious thromboembolic adverse events: 7% in rFVIIa group, 2% in 
placebo group (P=0.12)
Europe/AustralAsia NovoSeven Patient: 36 䤎 No significance of baseline ICH volume
ICH Trial Investigators15) Placebo: 12 䤎 No difference of percent changes in ICH volume between baseline and
24 hours
䤎 No difference of total hemorrhage volume (ICH+IVH)
䤎 No significance of improvement between baseline and 90 days
䤎 No noticeable difference in types, frequency, or severity of adverse events
US phase IIA trial16) Patient: 35 䤎 33 patients experienced 186 adverse events, which occurred with similar
Placebo: 5 frequency in each five groups
䤎 10 thromboembolic adverse events (1 DVT, 1 cerebral infarction, 2
pulmonary embolism, and 6 ischemic ECG changes or cardiac enzyme
elevation), 
䤎 No consumption coagulopathy or dose-related increase in edema-to-ICH 
volume ratio
Genetic and Environmental Patient: 133 䤎 Mortality at 90 days: no significant difference between two groups (P=0.99)
Risk Factors for Hemorrhagic Placebo: 96 䤎 Absolute mortality benefit for rFVIIa patients versus placebo: 11% (P=0.02)
Stroke (GERFHS) Study10) 䤎 Death or severe disability at 3 months (mRS 4 to 6 and e-GOS 1 to 4): 69%
of placebo and 53% of rFVIIa-treated patients (P=0.004)
䤎 Thromboembolic adverse events: 2% of placebo and 7% o rFVIIa patients
(P=0.12)
GCS: Glasgow Coma Scale, ICH: intracerebral hemorrhage, IVH: intraventricular hemorrhage, rFVIIa: recombinant activated factor VII,
mRS: modified Rankin scale, GOS-E: Extended Glasgow Outcome Scale, DVT: deep vein thrombosis, ECG: electrocardiogram
structure resembling human activated factor VII,
manufactured using DNA biotechnology. Being a
biotechnology product, it is not derived from human or animal
plasma, thus eliminating the risk of human blood-transmitted
disease. rFVIIa is usually administered by slow IV bolus
injection and it has a predictable, well-characterized
pharmacokinetic profile (half-life of 2.7 hours). rFVIIa may
be acting locally at the site of tissue and vascular wall injury,
by binding to exposed tissue factor to produce thrombin. Even
though this amount of thrombin may not be sufficient to cause
significant coagulation, it can accelerate platelet activation.
The activated platelet accumulating at the site of injury will
provide additional surface activate factor X to activated factor
X to mediate additional thrombin production. This ‘thrombin
burst’will ultimately mediate the activation of factor XIII and
the conversion of fibrinogen into fibrin, thus enhancing
coagulation. In addition, rFVIIa activates thrombin-activatable
fibrinolysis inhibitor, thus stabilizing the recently formed
blood clot.5)22) Moreover, there is increasing evidence showing
that rFVIIa, in high concentration, can directly activate factor
X on activated platelets, monocytes, or phospholipid vesicles
independently of tissue factor.13)
Although rFVIIa has a good safety profile in patients with
hemophilia and other bleeding disorders, experience with
rFVIIa in older, moncoagulopathic patients with risk factors
for cardiovascular or cerebrovascular disease was considered
limited. Accordingly, the investigator’s main objective was to
focus on treatment-related thrombo-embolic or coagulation-
related adverse events. On current situations, randomized and
controlled clinical trials (RCT) of this potential hemostatic
agent for acute ICH is warranted. The effectiveness and safety
of hemostatic drug therapies, compared against placebo or
open control, in RCT should be proven the following
hypotheses: 1) Do hemostatic drug therapies reduce the risk of
a poor clinical outcome after ICH? 2) Are hemostatic drug
therapies safe in the treatment of acute ICH? 3) Do hemostatic
drug therapies reduce ICH expansion in the first 1 or 2 days? 
One review of RCT of hemostatic drugs for acute ICH in
published or unpublished databases identified four RCTs
(ATICH, rFVIIa EurAsia IIA, rFVIIa IIB, and rFVIIa USA
IIA).23) One of the four RCTs was a phase II RCT of
intravenous epsilon-aminocaproic acid (EACA) compared
against supportive treatment alone, started within three hours
of PICH onset in adults (ATICH). ATICH stopped after the
enrolment of three participants; because recruitment had
been slow and the investigators decided that the rationale for
rFVIIa was better than EACA, they terminated ATICH and
participated in rFVIIa USA IIA and rFVIIa IIB instead. The
other three included studies were phase II RCTs, all funded
and conducted by Novo Nordisk, comparing the use of
various doses of intravenous rFVIIa against placebo, started
within four hours of ICH onset in adult. There are ongoing
RCTs of rFVIIa: one is a multinational phase III RCT
intending to recruit 675 participants and compare two doses
of rFVIIa with placebo [rFVIIa III (FAST)], and the other is
a phase II RCT intending to recruit 90 Japanese participants
and compare rFVIIa with placebo (rFVIIa Japan IIA). 
The safety of rFVIIa is surprisingly good considering its
mechanism of action, which one might expect to provoke
both thromboembolism and worsening of cerebral edema
around ICH. A recent summary of thromboembolic
complications related to the use of rFVIIa which were
reported to the USA Food ad Drug Administeration’s
system of passive surveillance of RCTs and everyday
clinical practice found that 14% of them occurred during use
of rFVIIa for ICH, and over half of thromboembolic events
attributed to rFVIIa were due to arterial thromboembolism.19)
The median time from rFVIIa treatment to the event was 24
hours, meaning that half of the events occurred more than 24
hours after rFVIIa treatment.19) In this review, the incidence
of the thromboembolic complications was 7%. There
appeared to be a two-fold increase in thromboembolic
serious adverse events in the rFVIIa group than in the
placebo one. This discrepancy could be explained by
underestimation of the hazards of rFVIIa use in all comers
with acute ICH, because of the exclusion of adults with a
recent history of thromboembolic or vaso-occlusive disease
half-way through the largest RCT (rFVIIa IIB).
Most of RCTs did not explore the effect of rFVIIa in pre-
specified subgroups possessing any or all of the other well-
recognized predictors of PICH outcome (e.g., hematoma size
and location, intraventricular extension of ICH, conscious
level on admission).21) Blood pressure may also be a
determinant of outcome, but blood pressure data were not
provided over time in any of the studies, nor were they used
to explore the effect of blood pressure on the efficacy of
rFVIIa.4) Standardization of these predictors between placebo
group and patient group should be warranted. 
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The costs of rFVIIa cannot be ignored. No economic
analyses have been performed specifically for treatments of
ICH. Recently, cost-effectiveness of rFVIIa in the treatment
of ICH was analyzed.8) They concluded that treatment of ICH
with rFVIIa 40 μg/kg and 160 μg/kg appeared to be cost-
effective. At the 80 μg/kg dose, rFVIIa was not only cost-
effective, but cost saving. Before rFVIIa is recommended for
widespread use, its cost-effectiveness must be assessed. 
Conclusions
Hematoma growth is one of the independent determinants
of neurological and functional outcomes after ICH.
Attenuation of growth is an important therapeutic strategy.
Hemostatic therapeutic intervention, given ultra-early in the
course of ICH, may thus improve clinical outcomes by
arresting ongoing bleeding and limiting in turn the size of
the hematoma. rFVIIa is a hemostatic drug approved to treat
bleeding in hemophilia or other coagulopathy; it has also
been reported to arrest bleeding in nonhemophilic cases. 
Overall, treatment with rFVIIa within four hours after the
onset of ICH limits the growth of the hematoma, reduces
mortality, and improves functional outcomes at 90 days,
despite a small increase in the frequency of thromboembolic
adverse events. More standardized, randomized, and
controlled clinical trials are nevertheless warranted.
Additionally, its cost-effectiveness must be assessed before
rFVIIa is recommended for widespread use.
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